Why the Fishman Regimen Should Not Be Used for Bronchiectasis
The Fishman regimen is not recommended for bronchiectasis because it involves routine use of inhaled corticosteroids (ICS), which current guidelines explicitly advise against in non-cystic fibrosis bronchiectasis due to lack of efficacy and increased infection risk.
The Core Problem with ICS in Bronchiectasis
Bronchiectasis is fundamentally a disease of neutrophilic inflammation, not eosinophilic inflammation 1. This is the critical distinction that makes the Fishman approach inappropriate:
- ICS target eosinophilic inflammation (effective in asthma/COPD) but have minimal impact on neutrophilic inflammation
- Bronchiectasis involves chronic bacterial colonization where immunosuppression from ICS can worsen outcomes
- The immunosuppressive properties of ICS can increase bacterial infection burden in airways already prone to chronic infection 1
What the Guidelines Actually Say
Both major 2025-2026 guidelines take a clear stance:
The European Respiratory Society (2025) issues a conditional recommendation suggesting NOT to routinely use inhaled corticosteroids in bronchiectasis 2. The American College of Chest Physicians (2026) guideline similarly does not recommend routine ICS use 3.
The evidence shows that over 50% of bronchiectasis patients are prescribed ICS without scientific justification, contrary to guideline recommendations 1. This represents widespread inappropriate prescribing.
When ICS Might Be Appropriate (The Only Exception)
ICS should only be used in bronchiectasis patients who have documented comorbid asthma or COPD 4, 5. In these specific cases:
- The ICS is treating the asthma/COPD component, not the bronchiectasis
- Careful monitoring for increased infections is mandatory
- Consider gradual dose reduction if asthma is well-controlled and bronchiectasis remains stable 5
What Should Be Used Instead
The evidence-based approach for bronchiectasis focuses on:
- Airway clearance techniques (strong recommendation) 2
- Long-term macrolides for patients at high risk of exacerbations (strong recommendation) 2
- Long-term inhaled antibiotics for chronic Pseudomonas aeruginosa infection in high-risk patients (strong recommendation) 2
- Pulmonary rehabilitation for impaired exercise capacity (strong recommendation) 2
- Mucoactive therapy (nebulized saline) to loosen secretions 4
Common Pitfall to Avoid
The most common error is reflexively prescribing ICS because the patient has "airways disease" and chronic cough. Bronchiectasis requires a fundamentally different treatment paradigm than asthma or COPD. The pathophysiology is infection and neutrophilic inflammation, not reversible airway obstruction or eosinophilic inflammation.
If a patient is already on ICS without documented asthma/COPD, consider tapering and discontinuing while monitoring for any change in symptoms 5.